Seyoung Park

h-index

Research activity per year

Fingerprint

Dive into the research topics where Seyoung Park is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Journal articles

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
THOR cohort 2 investigators, Siefker-Radtke, A. O., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Özgüroğlu, M., Valderrama, B. P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., Loriot, Y., Bastick, P., Sewak, S., Tran, B. & Pichler, M. & 31 others, Shariat, S., Rottey, S., Schatteman, P., Schrijvers, D., Verschaeve, V., Vulsteke, C., Barros Leite Ferreira, L. A., de Santana Gomes Andrea Juliana, P., Junior, J. A., Azevedo, S., Bastos, D., Borges, G., Dettino, A., Antonio, P. L., Luz, M., Martins, S., Mota, J. M., Toledo, J., Eigl, B., Finch, D., Gingerich, J., Dong, H., Huang, J., Jin, J., Pan, H., Sun, Z., Tian, Y., Wan, B., Wu, B., Xu, T. & Kramer, M., 01.2024, In: Annals of Oncology. 35, 1, p. 107-117 11 p.
Research output: Journal Articles › Journal articles › Research › peer-review
51 Citations (Scopus)

Seyoung Park

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Seyoung Park

Fingerprint

Collaborations and top research areas from the last five years

Research output

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial